Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Prestige Biologics Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4,756	1,582	29,507	45,435	15,383	36,775
Short-Term Investments	-	-	-	-0	-	-
Cash & Short-Term Investments	4,756	1,582	29,507	45,435	15,383	36,775
Cash Growth	-86.99%	-94.64%	-35.06%	195.36%	-58.17%	766.97%
Accounts Receivable	248.2	438.43	389.19	1,074	40.75	1,175
Other Receivables	1,155	4,525	1,265	999.61	2,036	7,077
Receivables	1,403	4,963	1,654	2,073	2,077	8,252
Inventory	30,878	26,909	17,805	6,833	12,034	9,697
Prepaid Expenses	178.15	224.64	222.48	147.86	129.05	62.23
Other Current Assets	3,549	7,170	6,446	15,754	213.14	73.2
Total Current Assets	40,764	40,848	55,636	70,242	29,835	54,860
Property, Plant & Equipment	227,360	228,406	233,052	234,435	227,107	149,989
Other Intangible Assets	1,282	1,032	676.96	1,047	1,108	1,791
Other Long-Term Assets	-	0	50	28.82	28.82	128.82
Total Assets	269,406	270,286	289,414	305,753	258,079	206,768
Accounts Payable	3,638	7,237	3,048	587.44	1,011	3,328
Accrued Expenses	504.58	504.58	6,636	3,149	1,612	841.4
Short-Term Debt	46,872	44,627	36,726	30,209	-	-
Current Portion of Long-Term Debt	16,225	14,156	10,824	12,914	10,604	6,434
Current Portion of Leases	59.63	12.17	66.17	39.68	98.57	134.63
Current Unearned Revenue	263.16	263.16	573.03	578.25	1,247	1,100
Other Current Liabilities	49,626	35,617	34,432	41,620	17,978	16,555
Total Current Liabilities	117,189	102,417	92,306	89,098	32,552	28,393
Long-Term Debt	29,944	32,666	125,414	116,846	107,900	71,428
Long-Term Leases	-	-	12.17	6.72	16.68	115.25
Other Long-Term Liabilities	-	-	-	-	0	-
Total Liabilities	147,133	135,083	217,732	205,950	140,468	99,936
Common Stock	38,876	38,876	30,751	30,554	30,554	23,603
Additional Paid-In Capital	341,501	341,501	257,963	256,059	256,059	202,489
Retained Earnings	-258,837	-245,907	-218,437	-189,063	-171,084	-121,366
Comprehensive Income & Other	732.73	732.73	1,406	2,253	2,082	2,105
Shareholders' Equity	122,273	135,203	71,682	99,803	117,611	106,832
Total Liabilities & Equity	269,406	270,286	289,414	305,753	258,079	206,768
Total Debt	93,101	91,461	173,043	160,016	118,619	78,112
Net Cash (Debt)	-88,345	-89,879	-143,536	-114,581	-103,236	-41,337
Net Cash Per Share	-1132.87	-1218.84	-2345.53	-1953.28	-1994.89	-930.07
Filing Date Shares Outstanding	77.89	77.75	61.5	61.11	61.11	47.21
Total Common Shares Outstanding	77.89	77.75	61.5	61.11	61.11	47.21
Working Capital	-76,425	-61,568	-36,670	-18,855	-2,716	26,467
Book Value Per Share	1569.77	1738.89	1165.54	1633.22	1924.65	2263.08
Tangible Book Value	120,991	134,171	71,005	98,756	116,504	105,041
Tangible Book Value Per Share	1553.31	1725.61	1154.53	1616.08	1906.52	2225.15
Land	10,565	10,565	10,565	10,565	10,565	10,565
Buildings	70,180	70,180	70,180	70,150	68,072	37,381
Machinery	67,798	59,390	56,143	37,728	37,566	22,529
Construction In Progress	74,189	95,463	90,441	126,395	117,130	78,220

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.